S100A9 and neoplasm: The IL-6/STAT3/S100A9 signaling pathway drives the proliferation, survival, invasion, and metastasis of tumor cells; meanwhile, it strongly inhibits the antitumor immune response (Johnson et al., 2018; Böttcher et al., 2022).